|
Urokinase
resources
DRUG INFO
Urokinase
Drug Name:
Urokinase
|
|
|
Indication: For lysis of acute pulmonary emboli
Pharmacology: Used for the treatment of pulmonary embolisms, the low molecular weight form of human urokinase consists of an A chain of 2,000 daltons linked by a sulfhydryl bond to a B chain of 30,400 daltons. Urokinase is an enzyme (protein) produced by the kidney, and found in the urine. There are two forms of urokinase which differ in molecular weight but have similar clinical effects. Abbokinase is the low molecular weight form. Abbokinase acts on the endogenous fibrinolytic system. It converts plasminogen to the enzyme plasmin. Plasmin degrades fibrin clots as well as fibrinogen and some other plasma proteins.
Mechanism Of Action: Cleaves the Arg-Val bond in plasminogen to produce active plasmin.
Drug Category: Thrombolytic Agents
Brand Names/Synonyms: Urokinase-type plasminogen activator precursor;uPA;U-plasminogen activator; Abbokinase (Abbott Laboratories)
Dosage Forms: Abbokinase is supplied as a sterile lyophilized white powder containing 250,000 IU urokinase per vial, mannitol (25 mg/vial), Albumin (Human) (250 mg/vial), and sodium chloride (50 mg/vial). Following reconstitution with 5 mL of Sterile Water for Injection, USP, Abbokinase is a clear, slightly straw-colored solution; each mL contains 50,000 IU of urokinase activity, 0.5% mannitol, 5% Albumin (Human), and 1% sodium chloride (pH range 6.0 to 7.5). Abbokinase is for intravenous infusion only
Absorption: Not Available
Interactions: Not Available
Chemical IUPAC Name: Human urokinase
Chemical Formula: C1376H2145N383O406S18
Half Life: 12 minutes. Small fractions of the administered dose are excreted in bile and urine
Drug Type: Approved Drug
# Accession No: BIOD00030
CAS Registry Number: 9039-53-6; 99821-47-3
| | |
